Sales & Marketing Reuters Pharma Barcelona 2023 - Day 2 Moving into Day Two – if you missed it, do be sure to catch up on yesterday’s coverage here – pharmaphoru
News Sage wilts as Huntington's prospect flunks trial Sage Therapeutics' run of bad news has continued with a failed phase 2 trial of dalzanemdor as a treatment for Huntington's disease
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
